You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 240 No. 25, December 15, 1978 TABLE OF CONTENTS
  JAMA
  •  Online Features
  ORIGINAL CONTRIBUTIONS
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on HighWire
 •Citing articles on Web of Science (51)
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Metastatic Non-Oat-Cell Bronchogenic Carcinoma

Therapy With Cyclophosphamide, Doxorubicin, Methotrexate, and Procarbazine (CAMP)

Jacob D. Bitran, MD; Richard K. Desser, MD; Thomas DeMeester, MD; Harvey M. Golomb, MD

JAMA. 1978;240(25):2743-2746.


Abstract

Fifty-four patients with metastatic non-oat-cell bronchogenic carcinoma were treated with cyclophosphamide, doxorubicin hydrochloride (Adriamycin), methotrexate, and procarbazine hydrochloride (CAMP). Eighteen of 51 of these patients with measurable disease showed an objective response to CAMP chemotherapy, with a median survival of 12.6 months. Eight of the 18 patients are still alive, and two have been in continuous remission for 20 and 26 months. Survival for patients with stable disease was 12 months, similar to that for patients demonstrating objective regression in response to CAMP treatment. Weight loss, performance status, and dominant site of metastases proved to be important prognostic factors. The CAMP regimen was well tolerated; there were only two drug-related deaths, both secondary to infectious complications.

(JAMA 240:2743-2746, 1978)



Author Affiliations

From the Departments of Medicine (Drs Bitran, Desser and Golomb), Michael Reese Medical Center and the University of Chicago Hospitals and Clinics, Chicago, and the Department of Surgery (Dr DeMeester), the University of Chicago Hospitals and Clinics, the University of Chicago-Pritzker School of Medicine, Chicago.


Footnotes

Reprint requests to Department of Medicine, Section of Hematology-Oncology, Michael Reese Medical Center, 2929 S Ellis, Chicago, IL 60616 (Dr Bitran).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

A Model to Select Regimens for Phase III Trials for Patients with Advanced-Stage Non-Small Cell Lung Cancer
Freidlin et al.
Clin. Cancer Res. 2003;9:917-922.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1978 American Medical Association. All Rights Reserved.